Referenser

References: 1.Produktresumé BELKYRA® injektionsvätska lösning 20161005 2. BELKYRA® Data on File: INT/0800/2016. 3. Ascher B, Fellmann J and Manheit G. ATX-101 (deoxycholic acid injection) for reduction of submental fat. Expert Review of Clinical Pharmacology. 2016; 9(9):1131-1143. DOI: 10.1080/17512433.2016.1215911. 4. De Fatta R and Ducic Y. Liposuction of the face and neck. Operative Techniques in Otolaryngology. 2007; 18:261-266. 5.Schlessinger, J. et al Perceptions ond practices in submental fat treatment: a survey of physicians and patients. SKINMed. 2013;11:27-31. 6. American Society for Dermatologic Surgery 2016 Consumer Survey on Cosmetic Dermatologic Procedures (N=7,322).11/18/2016 from: https://v.ww.asds.net/uploadedimages/2016%20Consumer%20Survey%20lnfographic.jpg. 7. Jones DH et al. REFINE-1, a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial with ATX-101, an lnjectable Drug for Submental Fat Reduction. Dermatol Surg. 2015; 0-1-12 DOI: 10:1097/DSS.0000000000000578. 8. McDiarmid J, et al. Results from a Pooled Analysis of Two European, Randomized, Placebo­controlled, Phase 3 Studies of ATX-101 for the Pharmacologic Reduction of Excess Submental Fat. Aesth Plast Surg. 2014; 38:849-860. DOI: 10.1007/s00266--014--0364-9. 9. ATX-101 (DEOXYCHOLIC ACID) lnjection Advisory Committee Briefing Materials (available for public release):1-127. Kythero Biopharmaceuticals, lnc.; Feb. 2015.Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/dermatologicandophthalmicdrugsadvisorycommittee/ucm436604.pdf (accessed January 19, 2017). 10. Rzany B, et al. Reduction of unwanted submental fat with ATX-101. Br J Dermatol. 2014; 170:445-453. 11. BELKYRA® Data on File: INT/0847/2016. 12. Humphrey S, et al. ATX-101 for Reduction af Submental Fat: a Phase III Randomized Controlled Trial. J Am Acad Dermatol. 2016; 75(4)788-797. http://dx.dai.org/10.1016/jaad.2016.04.028. (accessed November 29, 2016.) 13. BELKYRA® Data on File: INT/0051/2017. 14. Rotunda A. lnjectable Treatments for Adipose Tissue: Terminology, Mechanism, and Tissue lnteraction. Lasers Surg Med. 2009; 41:714-720. 15. Thuangtong R, et al. Tissue-selective effects of injected deoxycholate. Dermatol Surg. 2010; 36:899-908. 16. Bipacksedel BELKYRA® injektionsvätska lösning 20161005. 17. Jones DH, et al. Proper Technique for Administration of ATX-101 (Deoxycholic Acid lnjection): lnsights from an lnjection Practicum and Roundtable Discussion. Dermatol Surg. 2016;42:S275-S281. DOI: 10.1097/DSS.0000000000000875. 18. Dover JS, et al. Management of Patient Experience with ATX-101 (Deoxycholic Acid lnjection) for Reduction of Submentol Fat. Dermatol Surg. 2016: 42:S288-S299. DOI: 10.1097/DSS.00000000000000908. 19. BELKYRA® Data on File: INT/0792/2016. 20. Larson JD, et al. Defining the fat compartments in the neck: a cadaver study. Aesth Surq J. 2014;34(4):499-506.

Denna sida använder cookies. En cookie är en liten textfil som placeras på din dator och denna används för att du ska uppleva sajten på bästa sätt. .